2 completed. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Completed 2 |
Follow PLD: new trials by email Literature Review of PLD trials Research Report on PLD
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200) avelumab, PLD - Ovarian Cancer | Phase 3 | Completed | Pfizer | 566 | 2015-12-21 | 2023-07-10 |
| Evaluation of Optimal Treatment With Bevacizumab in Patients With Platinum-sensitive Recurrent Ovarian Cancer Carboplatin, PLD, Bevacizumab - Recurrent Platinum-sensitive Ovarian Cancer | Phase 3 | Completed | AGO Research GmbH | 682 | 2013-05-01 | 2021-07-13 |
AGO Research GmbH (1) · Pfizer (1)
Australia (2) · Austria (2) · Belgium (2) · France (2) · United Kingdom (2) · Canada (1) · Czechia (1) · Denmark (1) · Germany (1) · Greece (1) · Hong Kong (1) · Hungary (1) · Ireland (1) · Israel (1) · Italy (1)
PMID 32305099, PMID 34143970, PMID 37407274, PMID 37665777
2015 (1)